Search

everythinglearnresearchcommunity

for

Search:↓

Microneedling the scalp can cause sneezing, runny nose, and watery eyes due to nerve stimulation, histamine release, reflex actions, or sinus relief. Several users experience similar symptoms.

A user noticed baby hairs after combing out locs and has been applying castor, rosemary, and peppermint oil daily. They are curious about progress, sharing photos from different stages.

The conversation discusses the progress of Clascoterone (Breezula) for hair loss treatment, noting that COVID-19 delayed female trials by three months but Phase III trials for males are proceeding with a Special Protocol Assessment filed with the FDA. Users express hope for Breezula as an alternative to existing treatments like finasteride and minoxidil, despite concerns about its potential high cost.

Breezula is expected to launch in late 2026, with data being sent to the FDA in early 2026. The process is typical for a successful trial.

The conversation is about a potential new hair loss treatment called Breezula CB-03-01. Users are discussing updates on its development and sharing personal experiences with making or using it.

Breezula is being sold at Anagen Inc and Universal Labs, and users are discussing their experiences and results with it. There is also interest in the formulation process and inquiries about PP405.

Breezula results are awaited, but no updates have been posted. Users are uncertain about its promise.

The conversation discusses Fevipiprant, an asthma drug that may block CRTH2 and potentially stop male pattern baldness (MPB) without inhibiting DHT. It also mentions the use of finasteride and dutasteride for hair loss.

The conversation discusses using finasteride, dutasteride, minoxidil, and RU58841, along with a 10,000 graft hair transplant, to prevent magpies from targeting bald men. The title humorously references an eight-year-old's survey on magpies swooping bald men.

A humorous website where users upload and vote on hairlines is struggling due to lack of participation. The creator encourages people to join for fun and scalp justice.

A user who buzzed their hair, raising their confidence. Other users suggested trying finasteride to thicken the existing hair or using hair systems as an alternative. Additionally, toppik was suggested as a way to fill in thinning areas.

The conversation is about a page stealing personal photos from a subreddit and selling a questionable oil as a hair loss treatment. Users are frustrated and discussing the theft of their images and ineffective moderation.

The user is using minoxidil, finasteride, dermarolling, and other treatments for hair regrowth, showing promising results in the temple area. Despite some skepticism, there is optimism about potential improvement.

Breezula (clascoterone) is expected to be available by late 2026, showing good long-term results with minimal side effects. KX-826 (pyrilutamide) acts faster but is still in earlier development stages.

Microneedling can cause infections if not done carefully; users suggest using alcohol swabs and reducing needle depth to avoid issues. Proper sanitation and gentle pressure are key to preventing bleeding and infection.

Breezula's effectiveness is uncertain, with some users skeptical about its potential and others noting its recent availability on the grey market. A user reported success with a stack of Dutasteride (oral), Minoxidil (topical), and RU58841 (topical), achieving significant hair improvement after 18 months.

The conversation discusses the completion of a Phase II trial recruitment for Breezula (CB-03-01), a potential treatment for androgenic alopecia. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.

A phase 3 trial for Breezula (clascoterone solution) to treat male pattern hair loss has been listed, with 726 participants and a completion date of January 2025. Other treatments mentioned include Aneira Pharma's combination of minoxidil and latanoprost, Triple Hair's combination of minoxidil, latanoprost, and finasteride, and a new microneedling and LLLT device called StimuSIL.

User discusses potential hair loss treatment SCUBE3 and shares mixed opinions on its effectiveness. One user reports positive results after applying SCUBE3 following microneedling.

The group buy for CB-03-01, a topical anti-androgen for hair loss, was postponed and refunded due to issues with the product's form and solubility. The product, also known as Breezula, is an alternative to finasteride with fewer side effects, but its official release is delayed until 2021.

The conversation is about a user who experienced negative side effects and poor sleep after using an impure hair loss treatment 'CB' from Wuhan Hengheda Pharm, which did not offer a refund or proper customer service. The user had the product tested, confirming its impurity.

Breezula (clascoterone) Phase 3 hair loss trial results are delayed, with no official updates yet. The acne version is approved, but hair loss results are still pending.

Breezula® (Clascoterone) showed promising results in a Phase 2 trial for treating hair loss, being as effective as Propecia with no serious side effects. It might be released between 2021-2022, and a related acne treatment with the same active ingredient could be used in the meantime.

A user found that taking Zyrtec (Cetirizine) and Advil helped reduce their scalp inflammation and pain, potentially creating a better environment for hair growth. They have not used any other medication for hair loss or scalp issues.

SCUBE3 is available online but poses risks like tumor promotion and high costs. Users advise against using it due to health concerns and inefficacy as a standalone treatment.

A 39-year-old from Bangalore shared his successful hair transplant journey, which included 3537 scalp and 1521 beard grafts, boosting his confidence. He also started medication alongside the transplant.

The conversation is about the FDA approval of WINLEVI for acne treatment and the anticipation of Breezula, a hair loss treatment using the same active ingredient, which may indicate a positive future for Breezula's release. There is disappointment that Breezula's results are not optimal, but it is seen as progress in hair loss treatment.

Breezula's phase 3 results are expected in July or August, with commercialization possibly in two years. There are concerns about delays and effectiveness, and the cost may be high.

Breezula is a potential hair loss treatment, but recent updates suggest it may not be as promising as initially thought. Some users express skepticism about its effectiveness based on past results.

A user is participating in a phase 3 trial for Clascoterone, a topical acne medication that may stimulate hair growth, and will share results after 6 months. They will have a section of their hair shaved and marked with a tattoo for the study.